Lupin Q2 FY25 Earnings: Net Profit Jumps 74% to ₹853 Crore, Driven by Strong Sales

Mumbai-based Lupin Ltd, a major player in the pharmaceutical sector, reported a significant 74.1% year-on-year jump in consolidated net profit for the July-September quarter of FY25. The profit rose to ₹852.63 crore, up from ₹489.67 crore in the same period last year, largely driven by increased sales.

Revenue Growth and Regional Sales

Lupin’s consolidated revenue for the quarter reached ₹5,672.73 crore, marking a 12.6% increase from ₹5,038.56 crore in the previous year. Sales in North America rose by 5.6% to ₹1,971.1 crore, contributing 36% to Lupin’s global revenue. India’s formulation sales grew by 18.8%, totalling ₹2,009.6 crore, which made up 37% of the company’s global revenue.

Strong EBITDA Performance

The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) for the quarter rose to ₹1,382.7 crore, a 44.3% increase from ₹958.2 crore a year ago. The EBITDA margin also improved, reaching 25.2%, up from 19.4% in the prior year’s quarter.

US Market and ANDA Approvals

During the quarter, Lupin received approval for 10 Abbreviated New Drug Applications (ANDAs) from the US FDA. This brings Lupin’s total ANDA filings to 431, with 329 approvals so far. Currently, 40% of Lupin’s US revenue is generated from complex generics.

Management Insights

Nilesh Gupta, Lupin’s Managing Director, highlighted the company’s progress, noting strong performance in both India and the US, with double-digit growth in India and a robust pipeline supporting future expansion. Gupta emphasized Lupin’s commitment to enhancing operational efficiency and investing in technology to sustain growth.

About Lupin Ltd

Lupin Ltd. is an integrated pharmaceutical company that researches, manufactures, and markets formulations and active pharmaceutical ingredients (APIs). Based on IQVIA data, the company ranks third by prescription volume in the US and seventh in the Indian Pharmaceutical Market (IPM).

On November 8, 2024, Lupin share price opened at ₹2,144.90 and touched the day high of ₹ 2,156.70 as of 10:12 AM on NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.